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【Abstract】

Background

Rosuvastatin calcium with metformin improves diabetic renal injury, but the

mechanism is not yet fully understood. Objective To explore the mechanism of action of rosuvastatin calcium
with metformin improving renal injury in a rat model of streptozotocin (STZ) -induced type 2 diabetes mellitus
(T2DM). Methods

Forty clean-grade Wistar rats were equally randomized into a control group (group C), a

metformin group (group M), a metformin+low-dose rosuvastatin calcium group (group M+RL), and a
metformin+high-dose rosuvastatin calcium group (group M+RH) from July to October 2021. T2DM model was
established for three groups (except for group C) using intraperitoneal injection of STZ. The drug was administered
by intragastric administration to the groups as follows: an equal amount of 0.9% sodium chloride solution for group
C, metformin (200 mg/kg/d) for group M, metformin (200 mg/kg/d) suspension+rosuvastatin calcium (0.42
mg/kg/d) for group M+RL, and metformin (200 mg/kg/d) suspension+rosuvastatin calcium (0.83 mg/kg/d) for
group M+RH. Rats were sacrificed after 6 weeks of intervention, while their blood and kidney tissues were
collected. The extent of injury of kidney tissues was observed under a light microscope after being stained with HE,
and was analyzed using Image-Pro Plus 6.0 after being stained with periodic-acid Schiff, and Masson's trichrome,
respectively. The expression of glucose transporter 4 (GLUT4) mRNA in the renal tissue was measured by
real-time polymerase chain reaction (PCR), and the protein levels of GLUT4 were detected by Western blotting.
Results Compared with group C, the glomerulus of rats in the other three groups showed significant structural
damage, accompanied by inflammatory cell infiltration and interstitial fibrosis. Moreover，mRNA expression levels
of GLUT4 in these groups were significantly lowered (P<0.05). Furthermore, the protein levels of GLUT4 in
groups M and M+RL were lowered notably (P<0.05). The mRNA and protein expression levels of GLUT4 in group
M+RL or M+RH were higher than those of group M (P<0.05). In addition, the mRNA and protein expression levels
of GLUT4 in the M+RH group were higher than those in the M+RL group (P<0.05). Conclusion Rosuvastatin
1 / 13

GENERAL PRACTICE IN CHINA

calcium with metformin could reduce inflammatory cell infiltration in glomerular and tubular, alleviate glomerular
basement membrane thickening and tubular vacuolar degeneration, delay the interstitial fibrosis development, and
increase GLUT4 mRNA and GLUT4 protein expression in STZ-induced T2DM rats. Moreover, a higher dose of
rosuvastatin calcium showed a better effect. Our study indicated that rosuvastatin calcium combined with
metformin may achieve a renoprotective effect by regulating the expression of GLUT4 mRNA and protein in
T2DM rats, and this effect may be enhanced with the increase in the dose of rosuvastatin calcium.
【Key words】 Diabetes mellitus, Type 2; Rats; Renal protection; Kidney disease; Rosuvastatin calcium;
Metformin; Glucose transporter 4
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In recent years, the incidence of type 2 diabetes mellitus (T2DM) in China has increased significantly with economic
development, an increase in the proportion of elderly people, and an increase in the prevalence of overweight and obesity[1].
Vascular endothelial cell damage, inflammatory response, oxidative stress, and insulin resistance are independent risk factors
for the progression of T2DM[2]. Rosuvastatin calcium is a potent lipid-lowering agent with better hydrophilicity than other
drugs in its class and less damage to the liver. Some studies have shown that Rosuvastatin Calcium also has a protective effect
on the kidney, by reducing inflammatory factor levels, improving vascular endothelial function, antioxidant and improving
insulin sensitivity[3-4]. Metformin is a common clinical treatment for T2DM and protects renal tubular cells from
inflammation, apoptosis, reactive oxygen species (ROS) stress, endoplasmic reticulum (ER) stress, and
epithelial-mesenchymal transition (EMT) by activating adenylate-activated protein kinase (AMPK), as well as inhibiting
thylakoid apoptosis and renal tubular cell senescence[5]. It was found that rosuvastatin combined with metformin has
important clinical value in improving blood glucose and lipid levels, controlling inflammatory response, and alleviating
insulin resistance (IR) in T2DM patients[6]. The effects of rosuvastatin calcium combined with metformin on the histological
structure, mRNA, and protein expression of glucose transporter 4 (GLUT4) in the kidney of T2DM rats induced by
streptozotocin (STZ) were investigated in the study, in order to explore its protective effects and mechanism in the kidney
injury of T2DM rats.
1 Materials and Methods
1.1 Animals

A total of 40 healthy male Wistar rats of 8-week-old clean grade with a body mass of (200±20) g were

purchased from Jinan Panyue Experimental Animal Breeding Co. [SYXK (Lu) 2012-0043], and the rats were housed at room
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temperature of 21-25 ℃ with air circulation for 1 week for acclimatization. The experiment was reviewed and approved by
the Ethics Committee of the Ninth Sixth Hospital of the People's Liberation Army Joint Security Force (20210123). The
animal feed was prepared by Beijing Botai Hongda Biotechnology Co., Ltd. The main nutrients were 24.2% protein, 42.1%
carbohydrate and 25.4% fat.
1.2 Experimental drugs and reagents Rosuvastatin calcium (trade name: Cortin), manufactured by AstraZeneca
Pharmaceuticals (China) Co. Metformin (trade name: Gevalt), manufactured by Sino-American Shanghai Schweppes
Pharmaceutical Co. Neutral gum, anhydrous ethanol, and xylene were supplied by Sinopharm Chemical Reagent Co.
Ethylenediaminetetraacetic acid (EDTA) (pH 8.0) antigen repair solution, EDTA (pH 9.0) antigen repair solution, citric acid
(pH 6.0) antigen repair solution, phosphate buffer (PBS), autofluorescence quencher, bovine serum albumin, DAPI stain,
primary antibody, fluorescent secondary antibody, and anti-fluorescence quenching blocker were purchased from Wuhan
Google Biotechnology Co. Hematoxylin-Eosin (HE) staining solution, differentiation solution, blue return solution, RNA
extraction solution, and primers were provided by Servicebio.
1.3 Experimental Method
1.3.1 Model establishment, grouping, and feeding
1.3.1.1 Model establishment After 1 week of adaptive feeding, the rats were fed with high sugar and high-fat diet for 6
weeks, and the model was constructed by a single intraperitoneal injection of STZ (40 mg/kg). Fasting blood glucose
(FGB)>11.1 mmol/L suggests the successful establishment of T2DM induced by STZ.
1.3.1.2 Grouping and feeding

Forty Wistar rats were randomly divided into four groups: control group(group C),

metformin group(group M), rosuvastatin calcium low dose + metformin group(group M+RL), and rosuvastatin calcium high
dose + metformin group(group M+RH), with 10 rats in each group. Group C: 10 mg/kg/d 0.9% sodium chloride solution;
Group M: Metformin (200 mg/kg/d); Group M+RL: Metformin (200 mg/kg/d) suspension + Rosuvastatin calcium (0.42
mg/kg/d); Group M+RH: Metformin (200 mg/kg/d) suspension + Rosuvastatin calcium (0.83 mg/kg/d). After 6 weeks of
intervention, the rats were injected intraperitoneally with 10% chloral hydrate solution (1 mg/300 g) on the following day, the
abdominal cavity was incised and the kidneys were removed, and the kidney tissue specimens were collected for examination.
1.3.2 HE staining The HE staining procedure was performed as follows: (1)Kidney tissue was paraffin-embedded and
routinely dewaxed to water; (2)Hematoxylin staining was performed for 5 min, followed by rinsing using distilled water;
(3)Eosin staining for 1 min and rinsing again with distilled water immersion; (4)Dehydration was performed and sealed with
neutral gum; (5)the kidney tissue sections were observed and analyzed under light microscopy.
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1.3.3 Periodic Acid-Schiff (PAS) staining The Masson staining procedure was performed as follows: (1)Thin sections of
tissue are routinely dewaxed to water; (2)Stain with periodate for 10 min and rinse with distilled water; (3)Incubate with
Schiffer's reagent for 15 min, rinse with running water for 5 min, turn tissue dark pink and rinse with distilled water;
(4)Hematoxylin was re-stained for 2 min; (5)Dehydrated in gradient ethanol, and sealed with neutral resin. At least 3
randomly selected 200x fields of view in the section were photographed and the percentage of area positive for purple was
measured using Image-Pro Plus 6.0 software.
1.3.4 Masson staining The Masson staining procedure was performed as follows: (1)Paraffin sections of kidneys were
stained with potassium chromate; (2)iron hematoxylin was used for nuclei stain for 10 min, followed by rinse with distilled
water; (3)Ponceau acid fuchsin staining buffer was used for staining for 10 min followed with immersion in glacial acetic acid
aqueous solution; (4)Phosphomolybdic acid staining for 5 min; (5)Aniline blue was used for staining for 5 min, followed with
differentiation and transparent sealing. The percentage of blue collagen fiber area in the 200x field of view was detected using
Image-Pro Plus 6.0 software.
1.3.5 Real-time fluorescence quantitative polymerase chain reaction (PCR) for GLUT4 mRNA expression levels in kidney
issue of rat RNA was extracted from 100 mg of rat kidney tissue, reverse transcribed, and the gene was quantified according
to the ΔΔCt method for GLUT4 mRNA in rat kidney tissue. The PCR amplification primer sequences are shown in Table 1.
1.3.6 Western-blotting assay for GLUT4 protein expression levels in kidney issue of rat Kidney tissues were thoroughly
homogenized and completely lysed, the total protein solution was collected, added to 5 times protein loading buffer at a ratio
of 4:1, denatured in a boiling water bath, and GLUT4 protein expression level in kidney tissue was assayed by
Western-blotting after using sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
1.4 Statistical analysis SPSS 22.0 software was used for statistical analysis, and the measurement data was expressed as
mean and standard deviation. One-way ANOVA was used for comparisons between multiple groups, and LSD-t-test was used
for two-way comparisons between groups. P value<0.05 was considered statistically significant.
Table. 1 PCR amplified β-actin and glucose transporter 4 sequences

Primer name
β-actin

Primer sequence (3’~5’)

Upstream: TGCTATGTTGCCCTAGACTTCG
Downstream: GTTGGCATAGAGGTCTTTACGG
glucose transporter 4 Upstream: CCTGCCCGAAAGAGTCTAAAGC
Downstream: CTAAGAGCACCGAGACCAACG
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2 Results
2.1 HE staining results HE staining showed no pathological changes in the kidney tissue of group C rats, with closely
packed tubules and no obvious abnormalities in the glomeruli; Glomerular atrophy, decreased number of renal tubules,
infiltration of inflammatory cells, interstitial edema and hemorrhage in renal tissue, and brown pigmentation in renal
parenchyma in the kidny issue of M group; A large number of inflammatory cells infiltrated in the glomerulus and intercellular
substance, slightly edema renal tubules, eosinophilic substances in the lumen, pyknotic and hyperchromatic nucleus and
congested tubulointerstitial blood vessels in the kidny issue of M+RL group; the dilated tubules, hypertrophied glomeruli and
the thickened basement membrane in the kidny issue of M+RH group(Figure 1).
2.2 PAS staining results The PAS staining showed that the glomeruli in group C were uniform and smooth, with no
obvious pathological changes in the tubular basement membrane and thylakoid stroma, thin glomerular vascular collaterals,
and no glomerular hypertrophy or tubular pattern; The thickened capillary walls, collapsed capillary collaterals, thickened
tubular basement membranes, and tubular patterns was in M+RL group; The glomerular basement membranes were
significantly thicker and thylakoid cells were significantly more in M+RH group than the C group, and the tubular lumens
dilated in the M+RH group(Figure 2). The percentage of positive PAS staining area was 1.67±0.41% in group C, 5.32±1.72%
in group M, 4.91±0.83% in group M+RL, and 4.55±0.27% in group M+RH, with a statistically significant difference
(F=8.509, p=0.007). The percentage of positive PAS staining was higher in the M, M+RL, and M+RH groups than in the C
group (P<0.01).
2.3 Masson staining results The Masson staining results showed that the glomerular basement membrane and thylakoid
stroma were normal in group C, with no necrotic lesions and interstitial fibrosis; The M+RH group had a small number of
specific deposits in the glomeruli, mild tubular atrophy, and more blue collagen fibers in the interstitium (Figure 3); The
percentage of blue collagen fiber area was 2.33±0.82% in group C, 21.26±1.55% in group M, 14.08±6.40% in group M+RL,
and 9.86±2.19% in group M+RH, with a statistically significant difference (F=15.423, p=0.001); the percentage of blue
collagen fiber area in groups M, M+RL, M+RH, and M+RH was significantly different; The percentage of blue collagen fiber
area was higher in Group M, Group M+RL, and Group M+RH than Group C.; The percentage of blue collagen fiber area was
lower in Group M+RL and Group M+RH than Group M (P<0.05); These findings suggesting that the drug has a protective
effect on rat kidney tissue and that the protective effect is positively correlated with the dose of the drug
2.4 Comparison of GLUT4mRNA expression levels in the kidney tissue of rats The expression levels of GLUT4mRNA in
rat kidney tissues were 1.06±0.39 in group C, 0.27±0.03 in group M, 0.62±0.21 in group M+RL, and 1.02±0.34 in group
M+RH, and the differences were statistically significant when comparing the expression levels of GLUT4mRNA in rat kidney
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tissues of the four groups (F=10.526, P<0.001). Among them, the GLUT4mRNA expression levels in the kidney tissues of
rats in the M group and M+RL group were lower than C group, and the GLUT4mRNA expression levels in the kidney tissues
of rats in the M+RL group and M+RH group were higher than M+RL group (P<0.05).
2.5 Comparison of GLUT4 protein expression levels in kidney tissues of rats The results of WB showed that the
expression levels of GLUT4 protein in the kidney tissues of rats were 0.80±0.10 in group C, 0.23±0.04 in group M, 0.41±0.10
in group M+RL, and 0.53±0.04 in group M+RH, and the differences were statistically significant (F=50.764, P<0.001). In the
M, M+RL, and M+RH groups, the expression levels of GLUT4 protein in the kidney tissues of rats were lower than those in
the C group, while the expression levels of GLUT4 protein in the M+RL and M+RH groups were higher than those in the M
group and the M+RH group was higher than those in the M+RL group, the differences were statistically significant(P<0.05)
(Figure 4).

Notes: Group C=control group, Group M=metformin group, Group M+RL=rosuvastatin calcium low dose + metformin group, Group
M+RH=rosuvastatin calcium high dose + metformin group

Figure 1 Morphological changes of kidney tissues stained with H&E in each group of rat kidney tissue
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Figure 2 Morphological changes of kidney tissues stained with periodic-acid schiff in each griup of rat kidney tissue
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Figure 3 Morphological changes of kidney tissues stained with Masson's trichrome in each group pf rat kidney tissue

Figure 4 The relative expression levels of glucose transporter 4 protein in each group of rat kidney tissue
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3 Discussion
T2DM is a metabolic disease characterized by elevated blood glucose levels. In recent years, the prevalence of diabetes
mellitus has been increasing and the mortality rate remains high[7]. Affected by insufficient insulin secretion and defective
islet function, diabetes is at risk of developing chronic kidney disease (CKD), which is an important cause of death in diabetic
patients[8].
Statins have anti-inflammatory effects, reducing the number of inflammatory cells and the levels of cytokines and
C-reactive protein[9]. Rosuvastatin inhibits the formation of superoxide dismutase (SOD) associated with
ischemia/reperfusion (I/R) through the mevalonate–isoprene–like pathway and inhibits inflammatory cell infiltration[10]. The
results of this study showed that the combination of rosuvastatin calcium and metformin had anti-inflammatory effects, and
the results of HE and PAS staining showed that the combination can reduce the inflammatory cell infiltration process in the
glomerulus and tubules, the degree of interstitial edema and hemorrhage; The degree of glomerular and tubular damage and
renal histopathology was reduced by increase of drugs dose.
Statins can exert their protective effects on the kidney by inhibiting oxidative stress in renal tissues through
anti-inflammatory effects, delaying glomerular damage and promoting the proliferation of podocytes, and limiting thylakoid
cells. Rosuvastatin is a hydrophilic statin with a t1/2 of 19 h compared to atorvastatin's t1/2 of 14 h in plasma, which alone can
reduce LDL by 30%-50% alone and is more effective in anti-inflammatory and oxidative stress inhibition[11].
Renal tissue fibrosis is an important pathological mechanism leading to reduced kidney function. Studies have shown
that hyperlipidemia can lead to glomerulosclerosis and renal fibrosis. Rosuvastatin can reduce the accumulation of
triglycerides to achieve a lipid-lowering effect, objectively inhibit the function of myofibroblasts at the same time, reduce the
production of the extracellular interstitium, inhibit the reabsorption of proteins by the renal tubules, thus inhibiting tubular
interstitial fibrosis, and alleviate the process of renal fibrosis through Smad-dependent and Smad-independent
pathways[12-14]. The results of this study showed that the combination of rosuvastatin calcium and metformin significantly
improved the disorganization of collagen fibers, increased interstitial spaces, and increased fibrinoid necrosis in renal tissues
of T2DM rats, reduced vascular thrombosis, and exerted its effect on inhibiting renal fibrosis.
Statins are pleiotropic and may exert antioxidant properties by stabilizing renal vascular endothelial cells and scavenging
oxygen free radicals, thereby preventing renal ischemia[15]. It has been shown that rosuvastatin calcium exerts antioxidant
effects by inhibiting the superoxide anion (O2-), which is dependent on reduced coenzyme II and upregulating intracellular
antioxidants such as glutathione to alleviate oxidative stress. In addition, rosuvastatin calcium also reduces the expression of
activated caspase-3, inhibits apoptosis, and has a protective effect on the kidney[16-17].
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GLUT4 is a transmembrane glucose transporter located in the glomerulus, thick ascending branch of the loop, and
vascular smooth muscle. It is regulated by insulin, takes up glucose in an insulin-dependent manner, and plays an important
role in maintaining glucose homeostasis[18]. Studies have shown that statins can induce insulin resistance, reduce the
expression of GLUT4 in adipose tissue, cause insufficient secretion of the insulin-sensitizing hormone, reduce insulin cell
function, and induce new-onset diabetes (NODM). The effect on insulin-induced phosphorylation of protein kinase b and
GLUT4 transport to adipocyte membrane is more significant than that of pitavastatin[19]. At present, there is still some
controversy about whether there is a correlation between statin dose and NODM. The results of a large number of studies have
shown that high-dose statins have a higher risk of NODM. However, there is also a view that dose is not the key to increase the
risk of diabetes. TAGUCHII et al[20] found through a clinical study of 13 054 patients that different doses of pitavastatin had
no significant effect on the incidence of NODM. The results of this study showed that compared with the C group, the
expression levels of GLUT4 mRNA and GLUT4 protein in the kidney tissue of the rats in the M group were decreased,
suggesting that the combination of the two drugs can improve insulin resistance and affect blood glucose metabolism by
regulating the expression of GLUT4 mRNA and GLUT4 protein. At the same time, the degree of kidney damage in the M+RH
group was lower than that in the M+RL group, and the expression levels of GLUT4 mRNA and GLUT4 protein were higher
than those in the M+RL group, suggesting that the drug dose was positively correlated with renal protection.
In conclusion, rosuvastatin calcium combined with metformin can alleviate the process of glomerular basement
membrane thickening, renal tubular edema, and renal interstitial fibrosis by reducing glomerular and tubular inflammatory
cell infiltration, and these protective effects may be related to may be related to the regulation of renal GLUT4 mRNA
expression by rosuvastatin calcium in combination with metformin. The combination of the two drugs can significantly
increase the protective effect on the kidneys of T2DM rats, and the protective effect on the kidneys can increase with the
increase of the drug dose.
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